We have previously conducted exploratory clinical trials investigating VEGFRs peptide vaccination with and without multiple glioma oncoantigens, such as lymphocyte antigen 6 family member K (LY6K), DEP domain containing 1 (DEPDC1), kinesin family member 20A (KIF20A), and forkhead box M1 (FOXM1), in patients with primary and recurrent malignant gliomas, wherein treatment exhibited safety and yielded therapeutic effects in some patients [14,22,23]. The gene discussed is FOXM1; the disease is glioma.